Result of AGM

Nuformix PLC

03 March 2026

 

3 March 2026

Nuformix plc

("Nuformix" or the "Company")

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual General Meeting of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved by a show of hands.  The proxies received ahead of the AGM, are reported below:

	Resolution	Ordinary/ Special	For		Against		Total votes cast	Withheld
			No. of votes	%	No. of votes	%
1	To receive the annual report and accounts for the year ended 30 September 2025	Ordinary	214,955,860	99.92%	177,416	0.08%	215,133,276	8,248,030
2	To approve the Annual Report on Remuneration	Ordinary	220,295,243	99.84%	357,453	0.16%	220,652,696	2,728,610
3	To re-appoint Daniel Gooding as a director	Ordinary	220,637,188	99.85%	327,691	0.15%	220,964,879	2,416,427
4	To re-appoint Julian Gilbert as a director	Ordinary	220,625,354	99.85%	339,525	0.15%	220,964,879	2,416,427
5	To re-appoint Madeleine Kennedy as a director	Ordinary	217,650,945	99.84%	347,691	0.16%	217,998,636	5,382,670
6	To re-appoint Kreston Reeves LLP as auditor	Ordinary	220,393,106	99.73%	605,530	0.27%	220,998,636	2,382,670
7	To authorise the Directors to determine the auditor's fees.	Ordinary	219,520,242	99.37%	1,398,865	0.63%	220,919,107	2,462,199
8	To authorise the Directors to allot shares.	Ordinary	209,386,402	97.46%	5,449,425	2.54%	214,835,827	8,545,479
9	To authorise the Directors to disapply pre-emption rights.	Special	211,574,241	98.46%	3,311,586	1.54%	214,885,827	8,495,479
10	To authorise the Company to purchase its own shares.	Special	213,681,044	95.98%	8,956,820	4.02%	222,637,864	743,442
11	To authorise calling of a general meeting on 14 clear days' notice.	Special	222,647,463	99.88%	277,416	0.12%	222,924,879	456,427

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 2,109,749,903 ordinary shares of £0.0005 each. 

Enquiries:

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
CMC Markets
Douglas Crippen	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone] [e-mail]

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities.  Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com.

 

END